Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know

Megan L. Krause, Shreyasee Amin, Ashima Makol

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.

Original languageEnglish (US)
Pages (from-to)169-184
Number of pages16
JournalTherapeutic Advances in Musculoskeletal Disease
Volume6
Issue number5
DOIs
StatePublished - Oct 13 2014

Fingerprint

Antirheumatic Agents
Biological Products
Lactation
Rheumatoid Arthritis
Pregnancy
Pregnant Women
Joints
Family Planning Services
Chronic Pain
Autoimmune Diseases
Decision Making
Fetus
Rheumatologists
Newborn Infant

Keywords

  • biologics
  • DMARDs
  • lactation
  • pregnancy
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

@article{16f72520b20346d29510dcacf51face7,
title = "Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know",
abstract = "Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.",
keywords = "biologics, DMARDs, lactation, pregnancy, rheumatoid arthritis",
author = "Krause, {Megan L.} and Shreyasee Amin and Ashima Makol",
year = "2014",
month = "10",
day = "13",
doi = "10.1177/1759720X14551568",
language = "English (US)",
volume = "6",
pages = "169--184",
journal = "Therapeutic Advances in Musculoskeletal Disease",
issn = "1759-720X",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis

T2 - what the rheumatologist needs to know

AU - Krause, Megan L.

AU - Amin, Shreyasee

AU - Makol, Ashima

PY - 2014/10/13

Y1 - 2014/10/13

N2 - Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.

AB - Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.

KW - biologics

KW - DMARDs

KW - lactation

KW - pregnancy

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84910036466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910036466&partnerID=8YFLogxK

U2 - 10.1177/1759720X14551568

DO - 10.1177/1759720X14551568

M3 - Article

AN - SCOPUS:84910036466

VL - 6

SP - 169

EP - 184

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

SN - 1759-720X

IS - 5

ER -